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Background: Treatment of psychotic disorders consists primarily of second generation antipsychotics, which are
associated with metabolic side effects such as overweight/obesity, diabetes, and dyslipidemia. Evidence-based
clinical practice guidelines recommend timely assessment and management of these conditions; however, research
studies show deficits and delays in metabolic monitoring and management for these patients. This protocol article
describes the project ‘Monitoring and Management for Metabolic Side Effects of Antipsychotics,’ which is testing an
approach to implement recommendations for these practices.
Methods/Design: This project employs a cluster randomized clinical trial design to test effectiveness of an evidence-
based quality improvement plus facilitation intervention. Eligible study sites were VA Medical Centers with ≥300 patients
started on a new antipsychotic prescription in a six-month period. A total of 12 sites, matched in pairs based on scores on
an organizational practice survey, were then randomized within pairs to intervention or control conditions.
Study participants include VA employees involved in metabolic monitoring and management of patients treated with
antipsychotics at participating sites. The intervention involves researchers partnering with clinical stakeholders to facilitate
tailoring of local implementation strategies to address barriers to metabolic side-effect monitoring and management. The
intervention includes a Design Phase (initial site visit and subsequent development of a local implementation plan);
Implementation Phase (guided by an experienced external facilitator); and a Sustainability Phase. Evaluation includes
developmental, implementation-focused, progress-focused and interpretative formative evaluation components, as well
as summative evaluation. Evaluation methods include surveys, qualitative data collection from provider participants, and
quantitative data analysis of data for all patients prescribed a new antipsychotic medication at a study site who are due
for monitoring or management of metabolic side effects during the study phases. Changes in rates of recommended
monitoring and management actions at intervention and control sites will be compared using time series analyses.
Discussion: Improving monitoring for metabolic side effects of antipsychotics, as well as promoting timely
evidence-based management when these effects emerge, will lead to improved patient safety and long-term outcomes.
This article discusses key strengths and challenges of the study.
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Psychotic disorders are prevalent, disabling and costly
among Veterans receiving healthcare in the U.S. Depart-
ment of Veterans Affairs (VA) and elsewhere. For example,
while 3.4% of VA service users have a diagnosis of schizo-
phrenia, patients with this serious mental illness (SMI) ac-
count for 11.7% of VA healthcare costs [1]. In Fiscal Year
(FY) 2010, about 242,000 patients with a psychotic disorder
diagnosis (e.g., schizophrenia, bipolar disorder) were
treated in the VA [2]. Over 90% of these patients who are
treated with antipsychotic medication are prescribed a
second-generation antipsychotic (SGA) medication. Unfor-
tunately, as was recently reinforced by the landmark Clin-
ical Antipsychotic Trials of Intervention Effectiveness
(CATIE) study [3], treatment with many SGAs is associ-
ated with metabolic side effects such as overweight/obesity,
diabetes, and dyslipidemia [4-7]. Failure to properly moni-
tor and manage these side effects can lead to increased risk
of mortality due to diabetic ketoacidosis [8] and cardiovas-
cular disease [9]. In addition to these treatment-emergent
adverse effects, patients with SMIs such as schizophrenia
already have a greater prevalence of obesity (42%) [10,11]
and diabetes (13%) [12] than the general population.
Recommendations for monitoring and management of
metabolic side effects
A national conference organized in 2002 by the VA Men-
tal Health Quality Enhancement Research Initiative (MH
QUERI) and others developed evidence- and expert
consensus-based recommendations for metabolic side-
effect monitoring [13]. Subsequently, similar recommen-
dations were developed by a joint panel of the American
Diabetes Association (ADA) and the American Psychiatric
Association (APA) [14]. Monitoring recommendations
from both of these sources were incorporated in the 2004
VA/Department of Defense (DoD) Psychoses Guidelines
update [15], and relevant evidence-based management
recommendations are contained in VA clinical practice
guidelines (CPG) for obesity [16], diabetes [17] and
dyslipidemia [18]. Briefly, monitoring of weight or body
mass index (BMI), fasting plasma glucose (FPG), and
fasting plasma lipids is recommended when a patient is
started on a new antipsychotic medication, with monthly
follow-up monitoring of weight/BMI, and FPG and lipid
profile monitoring at three to four months and annually
thereafter [13,14]. In addition, the ADA/APA panel sug-
gested using SGAs with lower propensity for weight gain.
Ziprasidone and aripiprazole are least likely to cause
weight gain, while olanzapine and clozapine are the most
likely [14]. Another recommendation from the CPG for
Screening and Management of Overweight and Obesity
[16] provides strong evidence-based recommendations
that overweight or obese patients be offered weight loss
interventions that combine dietary therapy, increasedphysical activity, and behavioral modification strategies.
Implementation of the overweight/obesity CPG is specific-
ally supported by the ‘MOVE!’ Weight Management Pro-
gram for Veterans, a national VA-designed program to
help Veterans lose weight, keep it off, and improve their
health [19].
Existing VA practice, patterns and outcomes
Both VA [7,20-22] and non-VA [23-25] studies have
found low rates of metabolic monitoring among pa-
tients treated with antipsychotics. Surprisingly, there are
no published studies that examine the rates for manage-
ment of metabolic side-effects that develop in the context
of newly-initiated antipsychotic treatment or antipsychotic
medication changes, although substantial improvement is
likely needed in these practices as well. In a recent study
of 32 VA facilities, metabolic monitoring frequency was
greater at baseline (i.e., within 30 days before to 30 days
after the new prescription date) than at initial follow-up
(i.e., 60 to 120 days after prescription date), although at
both times monitoring was low. For example, baseline
monitoring rates compared to follow-up rates were 67%
versus 49% for weight, 46% versus 27% for glucose or
hemoglobin A1c, and 32% versus 16% for LDL [20].
Preliminary studies and related developments
A previous project, ‘A Study of Strategies for Improving
Schizophrenia Treatment (ASSIST),’ compared the effect-
iveness of two strategies aimed at improving medication
management for schizophrenia – a team-based quality im-
provement strategy (Team QI) and a strategy involving a
single clinical opinion leader (OL) at six sites in two Vet-
erans Integrated Service Networks (VISNs). Both strategies
were aided by an evidence-based QI (EBQI) approach and
external facilitation (EBQI/F). While both Team QI and
OL strategies resulted in improvements in metabolic moni-
toring rates at the time of a new antipsychotic prescription,
neither strategy was clearly superior to the other. The
study suggested that: designating a provider or clinic to en-
sure completion of monitoring, and implementing a com-
puter routine that queried the VA electronic medical
record to identify patients due for monitoring were effect-
ive QI components.
Subsequently, in December 2007, the VA Office of In-
spector General (OIG) reported on their examination of
metabolic monitoring and management for patients on
atypical antipsychotics for ≥90 days [26]. Rates of monitor-
ing described in the OIG report were higher than in other
studies (e.g., 88% of patients had an FPG test in the past
year) because of longer observation periods than in other
studies. For obese or overweight patients (82% of the sam-
ple), 21% did not have any record of a weight management
intervention. Of the 17% of patients with elevated glucose
in the past three years, only 49% had documented
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at any metabolic management within the past year, rather
than examining timely intervention for abnormal monitor-
ing results. The OIG report and VA research clearly dem-
onstrate the need for more timely guideline-concordant
management of antipsychotics’ metabolic side effects.
Also in 2007, MH QUERI and the South Central
Mental Illness Research, Education and Clinical Center
(MIRECC) sponsored an expert panel meeting to fur-
ther operationalize metabolic monitoring recommenda-
tions and consider applicability of the other VA/DoD
CPG recommendations for management of metabolic side
effects. Panel discussions informed a subsequent task force,
the Atypical Antipsychotic Workgroup, formed by VA
Mental Health Services in 2008. Both groups, after review
of existing guidelines and relevant scientific literature,
noted the importance of broad dissemination of evidence-
based and expert consensus-based recommendations for
monitoring and managing antipsychotic side effects.
MIRECC initiative on antipsychotic monitoring
improvement project
Following the Atypical Antipsychotic Workgroup report,
Mental Health Services funded the MIRECC Initiative on
Antipsychotic Monitoring Improvement (MIAMI) Project
to broadly disseminate metabolic monitoring and manage-
ment recommendations along with promising tools, strat-
egies, and technical assistance to support relevant quality
improvement efforts. The MIAMI Project team included
clinical and research experts in psychopharmacology, SMI,
and implementation science, who further operationalized
metabolic monitoring and management recommenda-
tions. The MIAMI Project included:
1. A national training meeting (May 2010) attended by
approximately 100 providers and clinical managers;
2. The MIAMI Project Technical Assistance Center
(TAC) to assist providers and clinical managers in
developing quality improvement efforts and to
provide additional information on MIAMI Project
tools/resources; and
3. A VA intranet website (http://vaww.mirecc.va.gov/
miamiproject), with links to relevant clinical practice
guidelines, educational resources, and weight
management resources.
Available MIAMI Project tools include examples of
computerized clinical reminders, a poster summarizing
monitoring and management recommendations, an auto-
mated computer routine to identify patients due for initial
metabolic monitoring, and a psychoeducational weight
management program [27,28].
The protocol presented in this article is for the project,
‘Monitoring and Management for Metabolic Side Effectsof Antipsychotics,’ which is testing an EBQI/F imple-
mentation intervention to enhance uptake of evidence-
based tools and strategies to improve monitoring and
management of metabolic side effects of antipsychotics
concurrently with the MIAMI Project’s VA national im-
plementation effort. We anticipate that the national imple-
mentation effort will improve care overall, although the
improvement is likely to be variable as there are a substan-
tial number of facilities that have fewer resources and
more difficulty mounting QI efforts, and that do not have
formal coordination between mental health and primary
care clinics for managing metabolic side effects in patients
taking antipsychotics. Therefore, we are studying the na-
tional implementation effort at multiple sites, using a clus-
ter randomized design, assessing organizational challenges
at these sites, and testing an intervention that includes
EBQI [29,30] and external facilitation [31,32] strategies to
customize, adapt and enhance the impact of local strat-
egies for implementation of the national QI initiative. We
stratified sites based on scores on an organizational prac-
tice survey, and randomized at the site level, recognizing
that organizational context is likely to be a strong pre-
dictor of implementation success. Results will inform
ongoing VA implementation of tools and strategies to im-
prove metabolic monitoring and management, as well as
future implementation research to improve care at all VA
facilities, not just sites that have adequate resources and
QI infrastructure.
Study objectives
1. To test the effect of an EBQI/F intervention as an
augmentation to the national implementation
initiative on monitoring of metabolic side effects of
antipsychotics in sites likely to encounter greater
challenges to implementation (see Site Selection
below).
2. To test the effect of the EBQI/F intervention as an
augmentation to the national implementation
initiative on management of metabolic side effects of
antipsychotics in sites likely to encounter greater
challenges to implementation.
3. To assess the direct costs of the EBQI/F
intervention, and explore potential variations in
costs of the EBQI/F intervention in sites with lower
versus higher levels of organizational challenges.
Methods
This study employs a cluster randomized clinical trial de-
sign, with matched pairs of VA facilities defined as the
clusters, to test the effectiveness of an EBQI plus facilita-
tion (EBQI/F) intervention combined with the ongoing
national quality improvement initiative (MIAMI Project)
at six sites (intervention sites) compared to six matched
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ment initiative alone (control sites). The extent to which
metabolic monitoring and management recommendations
are followed will be examined at the intervention sites
over three six-month intervals: the Pre-implementation
Phase, defined as the six-month period prior to the initial
EBQI site visit at the intervention sites; the Implementa-
tion Phase, which includes active external facilitation
(EBQI/F); and the Sustainability Phase, during which the
research team continues to evaluate the extent of meta-
bolic monitoring and management, but external facilita-
tion is not provided (see Figure 1). Each control site will
be examined over the same three six-month periods as the
matched intervention site. During the initial site visit, and
for a variable period of time following the visit (the EBQI
Design Phase), each intervention site’s EBQI participants
will work with the facilitator to develop a local implemen-
tation plan. If preliminary results indicate that the EBQI/F
intervention is successful, control sites will be offered
the EBQI/F intervention in a Crossover Phase at the con-
clusion of the study.
Site selection
Our systematic site selection method used data extracted
from national VA databases and determined that 99 VA
Medical Centers had 300 or more patients with a new
antipsychotic prescription in the first six months of FY08.
Next, to identify sites likely to perform relatively poorly in
management of metabolic side effects, we determined the
proportion of patients at each site who received a primary
or secondary stop code for an encounter with the VA’s
‘MOVE!’ Weight Management Program in the six months
following the new antipsychotic prescription. We used the
referral to the ‘MOVE!’ Program as an indicator of pro-
vider attention to adverse medication side effects, since
weight gain is a common side effect of antipsychotic use.
The median proportion of patient encounters with the
‘MOVE!’ Program per site was 1.2% and the range was 0%
to 4.3%. These results are similar to a previous finding that
only 2% of overweight patients with schizophrenia receive
recommended medication changes [33].
We then excluded sites not involved in research, using
the Office of Research & Development’s directory ofStudy Ph
EBQI Site Visit
Pre implementation EBQI Design Im
Evaluation 
6 months variable
Figure 1 Study timeline of implementation/evaluation phases for eacresearch programs. From those sites located within the
contiguous 48 states with active research programs, we
contacted the mental health clinical manager at the 24
sites with the lowest proportions of ‘MOVE!’ Program
utilization (range 0% to 0.66%). Three of the 24 sites were
excluded because of an active or planned research project
to study metabolic monitoring and/or management. Two
sites were excluded because they already had primary care
clinicians integrated into mental health clinics. Two sites
declined to participate, and leaders at three other sites did
not respond to repeated requests for participation in the
project. Leaders at the remaining 14 sites attended confer-
ence calls with the study PI to obtain further information,
and each agreed to have their site included in the final site
selection pool. Each completed a brief survey, adapted
from a VA Clinical Practice Organizational Survey that in-
cluded questions on provider stress and ability to pursue
practice change [34,35]. Survey scores ranged from 16.1 to
74.2 on a 100-point scale, with higher scores indicating
higher levels of stress and lower capacity to pursue prac-
tice change. Sites were ranked according to survey scores.
The 12 sites with the highest scores were invited to par-
ticipate in the study, and all accepted. We used the ranked
list of sites to identify matched pairs with comparable sur-
vey scores, and then randomly selected one site from each
pair to receive the intervention, using a random number
generator tool available at www.random.org. The mean
survey score of the intervention sites was 48.9 compared to
51.1 for the control sites. Shortly after this matching, two
of the sites withdrew from study participation; however,
fortunately, the remaining two sites that had not initially
been selected for study inclusion agreed to participate.
Both of these sites had low scores on the Clinical Practice
Organizational Survey, and thus did not affect the distribu-
tion of intervention and control sites on this inclusionary
variable. Soon after this change, another site withdrew
from the study; however, this occurred at about the same
time that one of the previous sites that had earlier declined
participation was now willing to participate. Both of these
sites had been randomized to the intervention arm, and so
the newly available site replaced the withdrawn site,
resulting again in 12 sites participating in the study: 6 inter-
vention sites and 6 control sites.ases: 
plementation Sustainability
Phases: 
6 months 6 months 
h matched pair of sites.
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Study participants include VA employees who are involved
in the monitoring and management of patients treated
with antipsychotics at participating sites and who com-
pleted surveys and interviews about related practices and
quality improvement efforts; and VA patients prescribed
antipsychotic medications, whose administrative and med-
ical record data are obtained and analyzed to assess meta-
bolic monitoring and management rates throughout the
study. Employee participants were recruited solely by the
research team to ensure confidentiality and avoid coercion.
The study was reviewed and approved by the VA Central
IRB and the Central Arkansas Veterans Healthcare System
Research & Development Committee.
EBQI/F intervention
Promoting Action on Research Implementation in
Health Services (PARIHS) is the conceptual framework
that guides and informs our intervention and evaluation
approaches for this study. In this framework, successful
implementation (SI) is represented as a function (f ) of
the nature and type of evidence (E), the qualities of the
context (C) in which the evidence is being introduced,
and the way the process is facilitated (F): SI = f(E, C, F)
[36]. ‘Evidence’ includes knowledge obtained through re-
search, clinician experiences, performance feedback, pa-
tient preferences, and other sources. ‘Context’ includes
factors that may affect implementation of evidence-
based practices, such as organizational culture/climate,
readiness-to-change, leadership quality, resources, and
the organization’s approach to evaluation. ‘Facilitation’ of
the intervention by external and/or internal change
agents can also affect implementation success [36,37].
The EBQI/F intervention, which involves researchers
partnering with clinical stakeholders, is designed in a man-
ner that is consistent with available research evidence and
reflects the knowledge and expertise of site participants re-
garding how to tailor the strategy to local needs, priorities
and resources. The intervention combines: EBQI processes
in the EBQI Design Phase to design and tailor the initial
implementation strategy to the local context, and external
facilitation to support, monitor, problem-solve and refine
implementation (as needed) during the study’s Implementa-
tion Phase. Further, through combining strategies and tools
included in the MIAMI Project (see above) with EBQI and
facilitation, the EBQI/F intervention provides a multifaceted
approach to improving care in this area [38-41].
For the current project, the automated computer routine
that was developed during the ASSIST Project (see above)
was revised to identify patients who had been prescribed a
new antipsychotic medication and were due for baseline or
initial follow-up monitoring. Reports generated by this rou-
tine list weight, BMI, and relevant laboratory test results, if
these tests were done. Additional computer routines weredeveloped to generate a list of patients with abnormal la-
boratory results, and indicate whether management actions
had been taken (e.g., prescription of a hypoglycemic agent
following an elevated glucose test). The research team
obtained approval from the VA Office of Information &
Technology to install this software at study sites.
EBQI design phase
The EBQI Design Phase includes an initial site visit and
subsequent development of a local implementation plan at
each site. In this phase, researchers contribute knowledge
about the evidence base for clinical care and implementa-
tion strategies, providing implementation tools and mate-
rials. Clinical stakeholders contribute local knowledge and
expertise needed to tailor implementation tools/strategies
to match organizational needs, priorities and capabilities.
EBQI participants at each intervention site include ap-
proximately two to four key staff (i.e., administrative
leaders, clinicians, nurses) involved in monitoring and
managing patients treated with antipsychotics who were
identified based on discussions between the study PI and
site mental health leaders.
The EBQI Design Phase includes consideration of site-
specific data collected in the developmental formative
evaluation (see below), such as current practices, barriers/
facilitators, key issues, and potential solutions in addressing
project goals. These data were gathered through qualitative
interviews conducted prior to the start of implementation
activities, analyzed using a rapid analysis approach [42,43],
and shared with EBQI participants to assist in development
of local implementation strategies. In addition, EBQI par-
ticipants were provided local performance data on meta-
bolic monitoring and management, extracted from VA
databases as described below for a six-month period prior
to the site visit.
During the EBQI Design Phase, EBQI participants con-
sider the QI tools/resources included in the MIAMI Pro-
ject as well as additional monitoring and management
tools and strategies that may be useful for local implemen-
tation. The duration of the EBQI Design Phase varies
across sites, an understandable phenomenon in imple-
mentation studies, where preparation, design and imple-
mentation are often classified as distinct phases and differ
depending on activities at each intervention site [44].
Implementation phase: active facilitation
The Implementation Phase of this study is guided by an
experienced and well-respected researcher (JLS), who
serves as the lead facilitator, and a co-facilitator. Facilitator
roles are to establish and leverage relationships with clin-
ical stakeholders in order to encourage, support and guide
them in executing the local implementation strategy.
It is expected that specific facilitation activities will
vary by site because the context/needs of individual
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remain consistent with key components of external
facilitation—including interactive problem-solving and
support—as identified in our earlier MH QUERI re-
search [37]. A time/activity log maintained by the facili-
tator will document all facilitation activities. This log
will be used to estimate costs of the EBQI/F interven-
tion as described in Data Analysis.
Evaluation
Evaluation will include formative and summative evaluation
activities. Formative evaluation (FE) is designed to identify
potential and actual influences on the progress and effect-
iveness of implementation efforts. It also helps optimize the
potential for success by providing a better understanding of
the processes involved, identifying and addressing needed
refinements to the implementation strategy, and assessing
the merit of using similar approaches in future implemen-
tation efforts [45]. The FE for this project included develop-
mental FE, implementation-focused FE, progress-focused
FE, and interpretive evaluation. Summative evaluation will
quantitatively assess the effectiveness of the EBQI/F inter-
vention in comparison to sites randomized to the study’s
control condition.
Developmental FE
The objectives of developmental FE are to identify deter-
minants of current practice regarding monitoring/man-
agement of metabolic side effects, identify available QI
resources, identify barriers/facilitators, and engage clinical
stakeholders in defining key issues and potential solutions
in addressing project goals. Key staff at intervention and
control sites have completed semi-structured telephone
interviews, providing their perspectives on these issues.
Participants also completed the Organizational Readiness
to Change Assessment (ORCA), described below.
Implementation- and progress-focused FE
The objectives of implementation-focused FE are to docu-
ment implementation processes and exposure of site
participants to the intervention, identify barriers to and
deviations from the planned local implementation strat-
egy, and modify the strategy as needed to overcome bar-
riers [45]. The objective of progress-focused FE is to
monitor progress in achieving implementation goals and
performance targets, enabling the facilitator to modify
intervention tools/strategies as needed to maximize poten-
tial for success [45]. The facilitator monitors implementa-
tion processes and progress through regular contacts with
a primary contact at each intervention site. Because the
facilitator’s attention to implementation- and progress-
focused FE activities will be directed exclusively to EBQI/F
sites, a survey of metabolic monitoring and management
practices (SMM) will be administered to Mental HealthService Chiefs at all sites prior to the start of the Implemen-
tation Phase and at the end of the Sustainability Phase.
Interpretive evaluation
The objective of interpretive evaluation is to obtain stake-
holder perspectives on the perceived value of the EBQI/F
intervention, barriers and facilitators encountered, satis-
faction with the implementation process, unintended con-
sequences, and any needed refinements. Only intervention
sites receive interpretive evaluation.
Stakeholder experiences with the intervention will be
assessed after the Implementation Phase through semi-
structured qualitative telephone interviews with the two
most involved participants in implementation activities at
each EBQI/F site. All interviews will be audio-taped and
transcribed for qualitative data analyses.
Summative evaluation
Data sources
Summative evaluation data sources include data extracted
from VA databases; medical record abstraction; and sur-
veys (SMM and the Organizational Readiness to Change
Assessment [ORCA]) administered to the participants.
The VA datasets contain patient demographics, inpatient
and outpatient encounters and associated diagnoses, phar-
macy and laboratory data, and vital signs. Patient data on
metabolic side-effect monitoring and management will be
collected on all Veterans meeting inclusionary criteria at
each site, and these data will be analyzed and presented at
the VA facility level.
Metabolic side-effect monitoring
Data will be extracted for all patients who were treated at
a study site and were prescribed a new antipsychotic
medication (defined as a ‘new antipsychotic start’ or the
addition of, or switch to, an antipsychotic medication that
had not been prescribed in the previous 180 days) [20]
and who would be due for monitoring or management of
metabolic side effects during any of the three six-month
phases of the study. If monitoring of a metabolic param-
eter (weight, glucose or hemoglobin A1c, and low-density
lipoprotein [LDL]) is documented as occurring within the
window of 30 days before to 30 days after a new prescrip-
tion, we defined this as completed ‘baseline’ monitoring.
The recommended 90-day ‘follow-up’ monitoring is de-
fined as monitoring of a metabolic parameter between 31
and 120 days following the new prescription date. For each
study site, the proportion of patients due for monitoring
that received monitoring at each time point for each par-
ameter will be calculated and aggregated for each month
in each study phase. All patients whose monitoring win-
dow ends within a given month will be included in the
denominator to calculate that month’s (baseline or
follow-up) monitoring rate.
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Performance of recommended management actions will be
assessed for patients with evidence of obesity (BMI ≥30),
hyperglycemia (plasma glucose ≥200 mg/dL), elevated
hemoglobin A1c (≥6.5), or elevated LDL (≥160 mg/dL) at
either the baseline or 90-day follow-up window, or weight
gain (>5% gain from baseline) at the 90-day follow-up win-
dow. Because VA datasets do not contain a reliable indica-
tor of whether a laboratory test was performed when the
patient was in a fasting state, these thresholds for man-
agement are set at a higher level than indicated in prac-
tice guidelines (e.g., 126 mg/dL for glucose). However,
diabetes practice guidelines indicate that two random
glucose tests with results ≥200 mg/dL may be used to
diagnose diabetes [17].
Medical records will be reviewed to better assess initi-
ation of management actions for patients who are found to
have abnormal results on any of the metabolic parameters.
This will not only allow for confirmation of the accuracy of
clinical management actions captured by the electronic
datasets, but will also allow for the inclusion of additional
information, such as documentation of decision-making
regarding antipsychotic choice and of counseling on diet
and exercise. Possible management actions and the data
source from which they are derived (VA datasets or chart
abstractions) are listed in Table 1. Monthly measures of a
site’s rate of management for metabolic side effects for
these patients will be constructed, combining data from
the two sources, using the data abstracted from the med-
ical record as the gold standard.
Data collection for and definition of covariates
A number of patient demographic and clinical characteris-
tics could affect the frequency of vital sign determinations
and laboratory tests for glucose or lipids. For example, pa-
tients with chronic heart failure should have weight
recorded frequently; patients with diabetes would have
more frequent fasting plasma glucose tests; and older pa-
tients and patients that have frequent primary care visits
for any reason would also be more likely to meet criteria
for recommended metabolic monitoring. Therefore, in
addition to birth date, gender and race, we will extract
diagnostic codes to identify pre-existing diagnoses of over-
weight/obesity, diabetes or dyslipidemia, as well as other
physical comorbidities. These variables, summarized over
site, will be included as covariates in the statistical models
of monitoring and management.
Assessing organizational readiness-to-change
The effect of organizational readiness-to-change on im-
plementation is being measured in this study with the
Organizational Readiness to Change Assessment (ORCA)
[46]. This instrument was developed for use in VA treat-
ment settings, assessing organizational readiness in termsof PARIHS domains of evidence, context and facilitation,
as well as the sub-elements of culture and leadership
[47,48]. The 15- to 20-minute survey was administered to
all provider participants at the 12 participating sites during
the Pre-implementation Phase and will be repeated at the
conclusion of the Sustainability Phase.
EBQI/F intervention costs
To estimate direct intervention costs (Objective 3), we
adapted the methodology used in the Translating Initiatives
in Depression into Effective Solutions (TIDES) study [44].
We will explore potential variations in intervention costs
at sites with lower versus higher organizational readiness-
to-change. We will assign costs to one of three categories
of implementation activities, as shown in Table 2.
Data analysis
Because weight gain is a common antipsychotic side effect
that increases risk of diabetes and cardiovascular disease
[6,9,11], and overweight/obesity is prevalent in patients
with psychotic disorders [10,11], the primary outcome
measures for the proposed project will be the extent to
which weight/BMI is monitored and to which overweight
or obese patients receive a guideline-concordant weight
management intervention. At each site, the proportion of
patients who receive baseline monitoring, follow-up moni-
toring, and management of metabolic abnormalities will
be measured each month against those who were due for
such actions during the same time period. We expect
EBQI/F intervention sites to gradually increase perform-
ance on monitoring and management measures over time.
Therefore, we will conduct a time series analysis of monthly
performance, with each site contributing six monthly per-
formance measures in each of the three phases of the study.
These analyses will estimate the change in rates of baseline
monitoring during the Implementation Phase due to inter-
vention (national quality improvement initiative with and
without EBQI/F), and allow comparison of these perform-
ance changes between sites receiving EBQI/F and those
not. Further, these analyses will allow within-phase changes
in monitoring rates to be compared between phases; e.g.,
for EBQI/F sites, is the monitoring performance change
during the Implementation Phase different from that dur-
ing the Sustainability Phase? We will similarly collect,
summarize, and analyze data from all patients due for
follow-up metabolic monitoring and metabolic manage-
ment (as defined in Table 1) during the three study phases.
We will compare the performance change over time
(a slope) between EBQI/F and control sites using a ran-
dom coefficients regression (RCR) that accounts for re-
peated measures taken within a site (see Additional file
1 for detailed explanation). The random coefficients
portion of the RCR accounts for site-to-site variability
within an intervention group (e.g., EBQI/F); that is, each
Table 1 Operationalization of measures for guideline-recommended metabolic management
Parameter Thresholds Management elements Operationalization Data source
Weight BMI ≥30, weight gain >5% Antipsychotic management Switch to medication w/ lower
propensity for weight gain
VA dataset
Lifestyle modification Counseling on diet, exercise, and
behavior modification within 30 days, OR
Chart review
Nutrition consult within 30 days, OR VA dataset
‘MOVE!’ Program encounter(s) within 30 days VA dataset
Medication Orlistat prescription within 30 days VA dataset
Glucose Plasma glucose ≥200 or Hgb A1c ≥6.5 Antipsychotic management Switch to medication with lower
propensity for elevated glucose
VA dataset
Lifestyle modification Counseling on diet, exercise, and
behavior modification within 30 days, OR
Chart review
Nutrition consult within 30 days, OR VA dataset
‘MOVE!’ Program encounter(s) within 30 days VA dataset
Follow-up Primary care/diabetes clinic visit within 30 days VA dataset
Medication Hypoglycemic agent within 30 days VA dataset
Lipids LDL ≥160 Antipsychotic management Switch to medication w/
lower propensity for elevated lipids
VA dataset
Lifestyle modification Counseling on diet, exercise, and
behavior modification within 30 days, OR
Chart review
Nutrition consult within 30 days, OR VA dataset
‘MOVE!’ Program encounter(s) within 30 days VA dataset
Follow-up Primary care/medicine visit within 30 days VA dataset
Medication Statin prescription within 30 days VA dataset
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tion group tend to be more alike than those from the
other intervention group. The RCR will also allow the
slopes to change with the phase of the study, thus allowing
us to also test whether performance change differs among
the phases over the study. For example, performance
change during pre-implementation is expected to be un-
changing or flat, but is expected to increase or trend up-
ward once EBQI/F begins.
Descriptive analysis of intervention costs will include
calculation of the number of providers involved in each
phase of the EBQI/F intervention (person count) and the
number of hours spent (person hours), with separate esti-
mates for clinical QI and research team activities. We will









coovariations in costs/intensity of the EBQI/F intervention at
the EBQI sites based on their readiness-to-change, using
data collected from the ORCA.
Power analysis
Based on our six EBQI/F intervention sites and six control
sites, Table 3 presents detectable slopes (i.e., within-phase
performance change) and changes in slopes (between
phases) assuming first: low, medium and high values for
the residual standard deviation (σ), the variances of the
random intercepts (va) and slopes (vb), and a first order
auto correlation, ρ, among the observations within a site;
then, power of at least 0.8 on a two-sided test made at the
0.05 significance level. Using ASSIST study findings, we
estimated residual standard deviations (σ) ranged fromes
mples of activities included
erson EBQI design meeting
oductory educational conferences by experts on research team
eting preparation
paration of site feedback reports
tomization of VA computer routines based on EBQI/F site visit requests
allation, pilot testing, and refinement of VA computer routines
rnal facilitation activities, including communication with site participants,
rdinating technical assistance, troubleshooting, and problem-solving
Table 3 Detectable differences in slope (% change per month)
Hypotheses Best case scenario Expected scenario Worst case scenario
Implementation has no effect over phase 3.7% 4.3% 5.1%
Implementation is no different from control at each phase 5.3% 6.1% 7.2%
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and within-site first order auto correlations (ρ) from
0.10 to 0.53. We used the minimum, midrange, and
maximum of the estimates to respectively present best
case (σ = 8.9%, va = 53.4, vb = 4.4, ρ = 0.10), expected
(σ = 10.1%, va = 137.6, vb = 5.3, ρ = 0.26), and worst
case (σ = 11.9%, va = 167.0, vb = 6.6, ρ = 0.53), scenar-
ios. Given the low rates of metabolic monitoring and
management observed in preliminary studies, the de-
tectable changes would be both possible and clinically
meaningful.
Trial status
The study is in the initial part of the Implementation
Phase. The initial EBQI site visits to the six implementa-
tion sites were completed in 2012, and facilitation activ-
ities have begun at the intervention sites. Retrospective
data are now being collected from all study sites.
Discussion
This study will build on prior research, demonstrating the
effectiveness of EBQI and facilitation to support tailored
implementation efforts at a site, and addresses an import-
ant aspect of clinical care for patients taking antipsy-
chotics. Improving monitoring for metabolic side effects
of antipsychotics, as well as promoting timely evidence-
based management when these effects emerge, will lead to
improved patient safety and long-term outcomes. This
project aims to increase uptake of the existing tools and
strategies that have been made available through a national
dissemination effort, although the facilitation process could
result in refinements of these elements or in development
of new improvement approaches. We discuss strengths and
initial challenges of the study below.
Site selection
The research team employed a systematic site selection
process rather than identifying a convenience sample of
frequently-utilized study sites. The selected sites thus are
more likely to be representative of the diversity of VA fa-
cilities, with respect to size, extent of academic affiliation,
resources available to pursue quality improvement efforts,
and scores on the organizational practice survey than
would have been the case if a convenience sample of sites
was selected. Systematic site selection ensures that study
findings will be broadly generalizable to the majority of
VA facilities, and enables the research team to identify
unique site implementation barriers and facilitators.Despite the potential benefits of this site selection
method, it also has caused challenges. While we pur-
sued IRB approval, our contacts at 3 of the 12 initially
selected sites indicated that the site would be unable to
participate in the study (e.g., because the leader who
originally agreed was no longer in the same position).
This experience suggests that a disadvantage of the sys-
tematic site selection process is that there may be more
attrition than when convenience sampling is employed;
perhaps investigators could develop retention strategies
to maintain site leaders’ interest in the study and en-
courage them to overcome participation barriers during
the sometimes lengthy waiting period between grant
submission and final funding. A study team could in-
clude back-up sites in the site selection approach, al-
though it may not be possible to activate a replacement
site once the study has started. Finally, investigators
should recognize that a site that withdraws after the
start of implementation activities should still be in-
cluded in an ‘intent-to-implement’ analysis.Timing of EBQI/F intervention
The grant application was written in 2008, with the ex-
pectation that the EBQI/F intervention could be initi-
ated concurrently with the planned initiation of the
MIAMI Project dissemination and implementation ac-
tivities. The national training for the MIAMI Project oc-
curred in 2010. However, due to the time elapsed
between grant submission and IRB approval, and a sub-
sequent delay related to obtaining data access and ap-
proval for use of our automated computer routines, the
study intervention site visits did not begin until late
2011, more than a year following the start of MIAMI
Project activities. Therefore, the project is studying the
added effect of EBQI/F on top of an ongoing dissemin-
ation effort, rather than a test of the effectiveness
of EBQI/F delivered at the time that a national imple-
mentation activity was rolled out, as was originally
envisioned. This means that during the ‘Pre-implemen-
tation Phase,’ both intervention and control sites have
MIAMI Project resources available, rather than this
period representing a baseline period prior to MIAMI
Project roll-out. However, relatively few providers avail
themselves of the educational information, computer
routines, or support services. Thus, we expect that the
EBQI/F intervention could result in substantial im-
provement in monitoring and management practices.
Owen et al. Implementation Science 2013, 8:120 Page 10 of 12
http://www.implementationscience.com/content/8/1/120Definition of abnormal ranges for glucose and LDL
Evidence- and consensus-based guidelines recommend
obtaining plasma glucose and lipid tests in the fasting
state, and intervening if test results are elevated (e.g.,
glucose ≥126 mg/dL; LDL ≥130 mg/dL) [17,18]. Unfor-
tunately, neither VA databases nor the narrative elec-
tronic medical record reliably indicate whether a patient
was fasting at the time of laboratory testing [20]. There-
fore, our study uses higher cut-off points (glucose ≥200
mg/dL; LDL ≥160 mg/dL) in order to increase the likeli-
hood that elevated glucose or LDL are, in fact, indicative
of diabetes or dyslipidemia respectively and warrant
management action(s), rather than being an artifact of
the non-fasting state. Other methods could be used to
determine whether the patient was likely to be fasting,
such as the length of time between the clinical visit and
the tests; the administration of glucose and lipid assays
on the same day, which could indicate that the tests
were intended to be drawn in the fasting state [49]; or
examining chart documentation for evidence that fasting
was recommended prior to testing. However, this infor-
mation may be incomplete and may vary among pro-
viders and sites. In contrast, using the higher cut-offs for
Objective 2 analyses will increase the likelihood that ab-
normal glucose or LDL tests are truly abnormal and re-
quire some form of management. This method reduces
false positives and increases specificity at the cost of re-
duced sensitivity.
We also chose to focus our Objective 2 examination of
management actions on those patients whose testing indi-
cated obesity (BMI ≥30) or weight gain (>5%), rather than
including the larger group of patients who warrant man-
agement for being overweight (BMI between 25 and 30). It
would not be feasible to review the medical records for all
patients with BMI greater than or equal to 25. Excluding
these patients, as well as patients with possible abnormal
glucose or LDL values, represents a limitation in the study
methods. We will further explore this issue by conducting
a sensitivity analysis by assessing the extent to which side-
effect management takes place for a subsample of patients
who are overweight, have blood glucose between 126 and
200 mg/dL, or have LDL between 130 and 160 mg/dL. We
will also explore whether chart documentation indicates
that a given blood test was meant to be obtained while
the patient was fasting. These sensitivity analyses could
provide useful information for future studies and could
be used to encourage inclusion of fasting notations in
the VA databases.
Despite the challenges and limitations of this complex
study of implementation strategies, this ongoing study will
yield insights into barriers and facilitators to monitoring
and management of antipsychotic side effects; determine
the effectiveness of EBQI combined with external facilita-
tion with regard to promoting successful implementation;and hopefully will improve care and patient safety at the
intervention sites. Study findings will inform subsequent
VA efforts to improve care and safety for patients pre-
scribed antipsychotic medications.
Additional file
Additional file 1: Detailed Description of Data Analysis Methods for
Objectives 1 and 2 Time Series Analysis.
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